Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable Terminated Phase 2 Trials for Aflibercept (DB08885)

IndicationStatusPhase
DBCOND0029236 (Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00509249Aflibercept in Treating Patients With Myelodysplastic SyndromesTreatment